Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
NCT00649207 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- March 31, 2013
- Enrollment
- 80 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.